Spain-based Hospital Miguel Servet is providing iCAD’s isotope-free radiation treatment for early-stage breast cancer, non-melanoma skin cancer and gynecological cancers.
The facility is using the iCAD’s Xoft Axxent Electronic Brachytherapy (eBx) system to treat patients, which received FDA and CE mark approval.
iCAD CEO Ken Ferry said: "We are pleased with the increased adoption of the Xoft System in Europe for a variety of cancers due to its versatility and the important advantages it delivers to patients and healthcare providers.
"The Xoft System is cleared to treat cancer anywhere in the body, requires minimal shielding and is mobile, allowing it to be used in different areas and facilities, including many smaller treatment rooms that may not accommodate larger equipment or protective shielding."
Using miniaturized x-ray as the radiation source, the Xoft system provides precise treatment directly to cancerous areas while sparing healthy tissue and organs.
According to iCAD, the mobility of the Xoft system allows to treat patients at multiple locations and does not need room redesign or construction investment.
The company will showcase the system at the third European Society for Radiotherapy and Oncology (ESTRO) Forum in Barcelona, which will be held from 24 to 28 April.
Hospital Miguel Servet is the largest facility in Aragon, which has 1,288 installed beds, 33 operating rooms and two national reference units for burns and multiple sclerosis.